Q-omics provides the consensus-scored MINK1 profile across patient tissues and cancer cell-line models. MINK1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MINK1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, MINK1 protein abundance shows 25,657 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, and GBM as cancer lineages where MINK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MINK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MINK1 survival associations across molecular data types. MINK1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MINK1 RNA expression–survival associations across cancer types. High MINK1 expression shows unfavorable associations in LIHC, LUSC, LAML and LGG, but favorable associations in ESCA and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MINK1 RNA expression.
This table summarizes MINK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MINK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MINK1 shows lower tumor expression in LUAD, KICH and COAD and higher tumor expression in LIHC, CHOL and HNSC. The LIHC box plot shows higher MINK1 RNA expression in tumor versus normal tissue (log2 FC = +1.103, t-test p < 0.001).
This table shows molecular features associated with MINK1 in patient tissues and cancer cell lines. In patient samples, MINK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MINK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
